Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses

Journal of Virological Methods

Volumn 208, Issue , 2014, Pages 107-114

  Richard, Jonathan ^a,b   Veillette, Maxime ^a,b   Batraville, Laurie Anne ^a,b   Coutu, Mathieu ^a,b   Chapleau, Jean Philippe ^a,b   Bonsignori, Mattia ^c   Bernard, Nicole ^d   Tremblay, Cécile ^a,b,e   Roger, Michel ^a,b   Kaufmann, Daniel E ^a,b,f   Finzi, Andrés ^a,b,g  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

ADCC responses; ADCC mediating antibodies; FACS based method; Gp120 Env; HIV 1

Indexed keywords

GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT PROTEIN;

ACCURACY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL KILLING; CELL POPULATION; CELL STRUCTURE; CELL SURFACE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; VIRAL CLEARANCE; BLOOD; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; PROCEDURES; VIROLOGY; CLINICAL ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NATURAL KILLER CELL; TARGET CELL;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL SURVIVAL; FLOW CYTOMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VIROLOGY;

EID: 84906484922     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.08.003     Document Type: Article

References (31)

1. Ahmad A., Morisset R., Thomas R., Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 1994, 7:428-437.
2. Alpert M.D., Harvey J.D., Lauer W.A., Reeves R.K., Piatak M., Carville A., Mansfield K.G., Lifson J.D., Li W., Desrosiers R.C., Johnson R.P., Evans D.T. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 2012, 8:e1002890.
3. Baum L.L., Cassutt K.J., Knigge K., Khattri R., Margolick J., Rinaldo C., Kleeberger C.A., Nishanian P., Henrard D.R., Phair J. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 1996, 157:2168-2173.
4. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., Marshall D.J., Whitesides J.F., Tsao C.Y., Kaewkungwal J., Nitayaphan S., Pitisuttithum P., Rerks-Ngarm S., Kim J.H., Michael N.L., Tomaras G.D., Montefiori D.C., Lewis G.K., Devico A., Evans D.T., Ferrari G., Liao H.X., Haynes B.F. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 2012, 86:11521-11532.
5. Chung A.W., Isitman G., Navis M., Kramski M., Center R.J., Kent S.J., Stratov I. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7505-7510.
6. Chung A.W., Rollman E., Center R.J., Kent S.J., Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 2009, 182:1202-1210.
7. Desormeaux A., Coutu M., Medjahed H., Pacheco B., Herschhorn A., Gu C., Xiang S.H., Mao Y., Sodroski J., Finzi A. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J. Virol. 2013, 87:2549-2562.
8. Finzi A., Xiang S.H., Pacheco B., Wang L., Haight J., Kassa A., Danek B., Pancera M., Kwong P.D., Sodroski J. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 2010, 37:656-667.
9. Gomez-Roman V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53-67.
10. Guan Y., Pazgier M., Sajadi M.M., Kamin-Lewis R., Al-Darmarki S., Flinko R., Lovo E., Wu X., Robinson J.E., Seaman M.S., Fouts T.R., Gallo R.C., DeVico A.L., Lewis G.K. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E69-E78.
11. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
12. Howell D.N., Andreotti P.E., Dawson J.R., Cresswell P. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J. Immunol. 1985, 134:971-976.
13. Kamya P., Boulet S., Tsoukas C.M., Routy J.P., Thomas R., Cote P., Boulassel M.R., Baril J.G., Kovacs C., Migueles S.A., Connors M., Suscovich T.J., Brander C., Tremblay C.L., Bernard N. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J. Virol. 2011, 85:5949-5960.
14. Kantakamalakul W., Pattanapanyasat K., Jongrakthaitae S., Assawadarachai V., Ampol S., Sutthent R. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J. Immunol. Methods 2006, 315:1-10.
15. Koup R.A., Sullivan J.L., Levine P.H., Brewster F., Mahr A., Mazzara G., McKenzie S., Panicali D. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J. Virol. 1989, 63:584-590.
16. Kramski M., Parsons M.S., Stratov I., Kent S.J. HIV-specific antibody immunity mediated through NK cells and monocytes. Curr. HIV Res. 2013, 11:388-406.
17. Kramski M., Schorcht A., Johnston A.P., Lichtfuss G.F., Jegaskanda S., De Rose R., Stratov I., Kelleher A.D., French M.A., Center R.J., Jaworowski A., Kent S.J. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J. Immunol. Methods 2012, 384:51-61.
18. Lewis G.K. Qualitative and quantitative variables that affect the potency of Fc-mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies. Curr. HIV Res. 2013, 11:354-364.
19. Lyerly H.K., Reed D.L., Matthews T.J., Langlois A.J., Ahearne P.A., Petteway S.R., Weinhold K.J. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retrovir. 1987, 3:409-422.
20. Madhavi V., Navis M., Chung A.W., Isitman G., Wren L.H., De Rose R., Kent S.J., Stratov I. Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes. Hum. Vaccines Immunother. 2013, 9:1011-1018.
21. Moore J.P., Willey R.L., Lewis G.K., Robinson J., Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 1994, 68:6836-6847.
22. Peretz Y., Ndongala M.L., Boulet S., Boulassel M.R., Rouleau D., Cote P., Longpre D., Routy J.P., Falutz J., Tremblay C., Tsoukas C.M., Sekaly R.P., Bernard N.F. Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin. Immunol. 2007, 124:57-68.
23. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., Carrington M., Kadie C.M., Carlson J.M., Heckerman D., Graham R.R., Plenge R.M., Deeks S.G., Gianniny L., Crawford G., Sullivan J., Gonzalez E., Davies L., Camargo A., Moore J.M., Beattie N., Gupta S., Crenshaw A., Burtt N.P., Guiducci C., Gupta N., Gao X., Qi Y., Yuki Y., Piechocka-Trocha A., Cutrell E., Rosenberg R., Moss K.L., Lemay P., O'Leary J., Schaefer T., Verma P., Toth I., Block B., Baker B., Rothchild A., Lian J., Proudfoot J., Alvino D.M., Vine S., Addo M.M., Allen T.M., Altfeld M., Henn M.R., Le Gall S., Streeck H., Haas D.W., Kuritzkes D.R., Robbins G.K., Shafer R.W., Gulick R.M., Shikuma C.M., Haubrich R., Riddler S., Sax P.E., Daar E.S., Ribaudo H.J., Agan B., Agarwal S., Ahern R.L., Allen B.L., Altidor S., Altschuler E.L., Ambardar S., Anastos K., Anderson B., Anderson V., Andrady U., Antoniskis D., Bangsberg D., Barbaro D., Barrie W., Bartczak J., Barton S., Basden P., Basgoz N., Bazner S., Bellos N.C., Benson A.M., Berger J., Bernard N.F., Bernard A.M., Birch C., Bodner S.J., Bolan R.K., Boudreaux E.T., Bradley M., Braun J.F., Brndjar J.E., Brown S.J., Brown K., Brown S.T., Burack J., Bush L.M., Cafaro V., Campbell O., Campbell J., Carlson R.H., Carmichael J.K., Casey K.K., Cavacuiti C., Celestin G., Chambers S.T., Chez N., Chirch L.M., Cimoch P.J., Cohen D., Cohn L.E., Conway B., Cooper D.A., Cornelson B., Cox D.T., Cristofano M.V., Cuchural G., Czartoski J.L., Dahman J.M., Daly J.S., Davis B.T., Davis K., Davod S.M., DeJesus E., Dietz C.A., Dunham E., Dunn M.E., Ellerin T.B., Eron J.J., Fangman J.J., Farel C.E., Ferlazzo H., Fidler S., Fleenor-Ford A., Frankel R., Freedberg K.A., French N.K., Fuchs J.D., Fuller J.D., Gaberman J., Gallant J.E., Gandhi R.T., Garcia E., Garmon D., Gathe J.C., Gaultier C.R., Gebre W., Gilman F.D., Gilson I., Goepfert P.A., Gottlieb M.S., Goulston C., Groger R.K., Gurley T.D., Haber S., Hardwicke R., Hardy W.D., Harrigan P.R., Hawkins T.N., Heath S., Hecht F.M., Henry W.K., Hladek M., Hoffman R.P., Horton J.M., Hsu R.K., Huhn G.D., Hunt P., Hupert M.J., Illeman M.L., Jaeger H., Jellinger R.M., John M., Johnson J.A., Johnson K.L., Johnson H., Johnson K., Joly J., Jordan W.C., Kauffman C.A., Khanlou H., Killian R.K., Kim A.Y., Kim D.D., Kinder C.A., Kirchner J.T., Kogelman L., Kojic E.M., Korthuis P.T., Kurisu W., Kwon D.S., LaMar M., Lampiris H., Lanzafame M., Lederman M.M., Lee D.M., Lee J.M., Lee M.J., Lee E.T., Lemoine J., Levy J.A., Llibre J.M., Liguori M.A., Little S.J., Liu A.Y., Lopez A.J., Loutfy M.R., Loy D., Mohammed D.Y., Man A., Mansour M.K., Marconi V.C., Markowitz M., Marques R., Martin J.N., Martin H.L., Mayer K.H., McElrath M.J., McGhee T.A., McGovern B.H., McGowan K., McIntyre D., McLeod G.X., Menezes P., Mesa G., Metroka C.E., Meyer-Olson D., Miller A.O., Montgomery K., Mounzer K.C., Nagami E.H., Nagin I., Nahass R.G., Nelson M.O., Nielsen C., Norene D.L., O'Connor D.H., Ojikutu B.O., Okulicz J., Oladehin O.O., Oldfield E.C., Olender S.A., Ostrowski M., Owen W.F., Pae E., Parsonnet J., Pavlatos A.M., Perlmutter A.M., Pierce M.N., Pincus J.M., Pisani L., Price L.J., Proia L., Prokesch R.C., Pujet H.C., Ramgopal M., Rathod A., Rausch M., Ravishankar J., Rhame F.S., Richards C.S., Richman D.D., Rodes B., Rodriguez M., Rose R.C., Rosenberg E.S., Rosenthal D., Ross P.E., Rubin D.S., Rumbaugh E., Saenz L., Salvaggio M.R., Sanchez W.C., Sanjana V.M., Santiago S., Schmidt W., Schuitemaker H., Sestak P.M., Shalit P., Shay W., Shirvani V.N., Silebi V.I., Sizemore J.M., Skolnik P.R., Sokol-Anderson M., Sosman J.M., Stabile P., Stapleton J.T., Starrett S., Stein F., Stellbrink H.J., Sterman F.L., Stone V.E., Stone D.R., Tambussi G., Taplitz R.A., Tedaldi E.M., Telenti A., Theisen W., Torres R., Tosiello L., Tremblay C., Tribble M.A., Trinh P.D., Tsao A., Ueda P., Vaccaro A., Valadas E., Vanig T.J., Vecino I., Vega V.M., Veikley W., Wade B.H., Walworth C., Wanidworanun C., Ward D.J., Warner D.A., Weber R.D., Webster D., Weis S., Wheeler D.A., White D.J., Wilkins E., Winston A., Wlodaver C.G., van't Wout A., Wright D.P., Yang O.O., Yurdin D.L., Zabukovic B.W., Zachary K.C., Zeeman B., Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557.
24. Pham T.N., Lukhele S., Hajjar F., Routy J.P., Cohen E.A. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 2014, 11:15.
25. Pollara J., Hart L., Brewer F., Pickeral J., Packard B.Z., Hoxie J.A., Komoriya A., Ochsenbauer C., Kappes J.C., Roederer M., Huang Y., Weinhold K.J., Tomaras G.D., Haynes B.F., Montefiori D.C., Ferrari G. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011, 79:603-612.
26. Richard J., Sindhu S., Pham T.N., Belzile J.P., Cohen E.A. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 2010, 115:1354-1363.
27. Smalls-Mantey A., Connors M., Sattentau Q.J. Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLOS ONE 2013, 8:e74858.
28. Smalls-Mantey A., Doria-Rose N., Klein R., Patamawenu A., Migueles S.A., Ko S.Y., Hallahan C.W., Wong H., Liu B., You L., Scheid J., Kappes J.C., Ochsenbauer C., Nabel G.J., Mascola J.R., Connors M. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 2012, 86:8672-8680.
29. Stratov I., Chung A., Kent S.J. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 2008, 82:5450-5459.
30. Tyler D.S., Stanley S.D., Nastala C.A., Austin A.A., Bartlett J.A., Stine K.C., Lyerly H.K., Bolognesi D.P., Weinhold K.J. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J. Immunol. 1990, 144:3375-3384.
31. Veillette M., Desormeaux A., Medjahed H., Gharsallah N.E., Coutu M., Baalwa J., Guan Y., Lewis G., Ferrari G., Hahn B.H., Haynes B.F., Robinson J.E., Kaufmann D.E., Bonsignori M., Sodroski J., Finzi A. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 2014, 88:2633-2644.